Penn Engineers have redesigned a key component of lipid nanoparticles (LNPs), the delivery vehicles behind mRNA vaccines, to steer the particles toward lymph nodes while reducing off-target delivery ...
Hosted on MSN
Penn scientists shift mRNA vaccine target
University of Pennsylvania engineers have developed 'aroLNPs,' a redesigned lipid nanoparticle that delivers mRNA primarily to lymph nodes while avoiding the liver. In animal studies, the particles ...
Penn Engineers have redesigned a key component of lipid nanoparticles (LNPs), the delivery vehicles behind mRNA vaccines, to steer the particles toward lymph nodes while reducing off-target delivery ...
Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...
The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis). Clinical analysis of AFFINITY trial: ...
Penn Engineers have redesigned a key component of lipid nanoparticles (LNPs), the delivery vehicles behind mRNA vaccines, to steer the particles toward lymph nodes while reducing off-target delivery ...
Top Left: Distribution of vaccines, "Naked mRNA" and "mRNA cloaked in a lipid coat." Bottom Left: Lung tissues in unvaccinated and vaccinated mice after SARS-CoV-2 challenge. Right: Schematic diagram ...
Researchers hold models of the aromatic rings they added to lipid nanoparticles, which could reduce the dosage mRNA vaccines need to achieve immunity. Penn Engineers have redesigned a key component of ...
“The more particles that reach the lymph nodes, the fewer particles each dose needs,” says Michael J. Mitchell, Associate Professor in Bioengineering (BE) and senior author of a new study in Journal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results